L-Lysine Acetate

We are L-Lysine Acetate CAS:57282-49-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


L-Lysine Acetate
 
An acetate salt of L-lysine. L-Lysine is an essential amino acid in human. It is metabolized to acetyl-CoA. It is widely used as an ingredient in infusion.

Cas.No 57282-49-2
Assay 99.0-101.0%
Specification White crystals or crystalline powder, characteristic odor, slightly acid taste
Applications Infusion
Packaging 25kg&50kg
Pharmacopeia JP,USP,EP
STORAGE Controlled room temperature in tight container

 
SPECIFICATION AND PROCEDURE

State of solution
(Transmittance)
Not Less Than 98.0%
pH 6.5~7.5
Specific rotation[α]20D +8.5~+10.0°
Specific rotation[α]25D +8.4~+9.9°
Ammonium (NH4) Not More Than 0.020%
Chloride (Cl) Not More Than 0.020%
Sulfate (SO4) Not More Than 0.020%
Iron (Fe) Not More Than 10 ppm
Heavy metals (Pb)** Not More Than 10 ppm
Arsenic (As2O3) Not More Than 1 ppm
Loss on drying Not More Than 0.20%
Residue on ignition Not More Than 0.10%
Related substances Not More Than 0.1%
Endotoxin* Less Than 6.0 EU/g
Assay (dry basis) 99.0~101.0%

· * The endotoxin-certified grade will be supplied on request.
· This product meets requirements of residual solvents listed in the current JP, USP and EP.
 

L-Lysine Acetate


Related News: Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anaemia). Patients with higher-risk MDS may progress to the development of acute leukaemia.17302-46-4 Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anaemia). Patients with higher-risk MDS may progress to the development of acute leukaemia.2-Chlorobutyric Acid The increase in environmental protection pressure has also increased the environmental protection expenditure of pharmaceutical manufacturing companies, which forced some small production capacity to withdraw from the market, increased industry concentration, and brought certain opportunities for API manufacturers.3972-65-4 The increase in environmental protection pressure has also increased the environmental protection expenditure of pharmaceutical manufacturing companies, which forced some small production capacity to withdraw from the market, increased industry concentration, and brought certain opportunities for API manufacturers.The increase in environmental protection pressure has also increased the environmental protection expenditure of pharmaceutical manufacturing companies, which forced some small production capacity to withdraw from the market, increased industry concentration, and brought certain opportunities for API manufacturers.

Related Products
Product Name
(Benzotriazol-1-Yloxy)Dipyrrolidinocarbenium Hexafluorophosphate View Details
2,6-Difluoro-3-nitrobenzonitrile View Details
N-(3-methyl-2,6-dihydro-1,3,5-oxadiazin-4-yl)nitramide View Details
Bromoacetyl chloride manufacturer ethyl 3,4-bis(2-methoxyethoxy)benzoate manufacturer 1,1,1,2,2,3,3,4,4,5,5,6,6-Tridecafluorooctane Cas:80793-17-5 manufacturer Diallyl sulfide manufacturer 1-Hydroxyethylethoxypiperazine manufacturer